ANAB Anaptysbio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ANAB

Price (delayed)

$25.75

Market cap

$704.76M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.09

Enterprise value

$420.55M

Highlights
The company's quick ratio has surged by 67% YoY and by 33% QoQ
ANAB's EPS has surged by 65% year-on-year but it is down by 49% since the previous quarter
The net income has soared by 64% YoY but it has decreased by 50% QoQ
The company's gross profit fell by 5% QoQ
ANAB's revenue is down by 5% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.anaptysbio.com/
Peers: OTIC ORIC

Key stats

What are the main financial stats of ANAB
Market
Shares outstanding
27.37M
Market cap
$704.76M
Enterprise value
$420.55M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.85
Price to sales (P/S)
9.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.9
Earnings
Revenue
$71.25M
EBIT
-$29.83M
EBITDA
-$29.29M
Free cash flow
-$23.05M
Per share
EPS
-$1.09
Free cash flow per share
-$0.84
Book value per share
$13.96
Revenue per share
$2.6
TBVPS
$14.49
Balance sheet
Total assets
$396.42M
Total liabilities
$14.48M
Debt
$0
Equity
$381.94M
Working capital
$372.66M
Liquidity
Debt to equity
0
Current ratio
26.74
Quick ratio
26.37
Net debt/EBITDA
9.7
Margins
EBITDA margin
-41.1%
Gross margin
100%
Net margin
-41.9%
Operating margin
-44.9%
Efficiency
Return on assets
-7.5%
Return on equity
-7.8%
Return on invested capital
-21.5%
Return on capital employed
-7.8%
Return on sales
-41.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANAB stock price

How has the Anaptysbio stock price performed over time
Intraday
-0.23%
1 week
-1.23%
1 month
3.29%
1 year
25.79%
YTD
19.77%
QTD
-0.69%

Financial performance

How have Anaptysbio's revenue and profit performed over time
Revenue
$71.25M
Gross profit
$71.25M
Operating income
-$31.99M
Net income
-$29.83M
Gross margin
100%
Net margin
-41.9%
The company's operating margin has surged by 89% YoY but it fell by 41% QoQ
ANAB's net margin has soared by 88% YoY but it has plunged by 58% from the previous quarter
ANAB's operating income has surged by 66% year-on-year but it is down by 34% since the previous quarter
The net income has soared by 64% YoY but it has decreased by 50% QoQ

Growth

What is Anaptysbio's growth rate over time

Valuation

What is Anaptysbio stock price valuation
P/E
N/A
P/B
1.85
P/S
9.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.9
ANAB's EPS has surged by 65% year-on-year but it is down by 49% since the previous quarter
ANAB's P/B is 51% lower than its 5-year quarterly average of 3.8 but 32% higher than its last 4 quarters average of 1.4
Anaptysbio's equity has decreased by 4.6% YoY and by 3.7% from the previous quarter
The stock's price to sales (P/S) is 94% less than its 5-year quarterly average of 156.2 and 45% less than its last 4 quarters average of 18.1
ANAB's revenue is down by 5% from the previous quarter

Efficiency

How efficient is Anaptysbio business performance
ANAB's return on sales has surged by 88% year-on-year but it has dropped by 58% since the previous quarter
The return on invested capital has dropped by 87% since the previous quarter but it has increased by 34% year-on-year
Anaptysbio's return on equity has surged by 61% YoY but it has shrunk by 50% QoQ
The ROA has soared by 60% YoY but it has shrunk by 53% QoQ

Dividends

What is ANAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANAB.

Financial health

How did Anaptysbio financials performed over time
The current ratio has surged by 68% year-on-year and by 34% since the previous quarter
The company's quick ratio has surged by 67% YoY and by 33% QoQ
ANAB's debt is 100% less than its equity
Anaptysbio's equity has decreased by 4.6% YoY and by 3.7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.